Video

Educated Patient® Leukemia and Lymphoma Summit: October 27, 2020

Author(s):

CURE Media Group

View the entire CURE® Educated Patient® Leukemia & Lymphoma Summit. A virtual event seeking to educate, inform and challenge the thinking of patients with leukemia and lymphoma.

View the entire CURE® Educated Patient® Leukemia & Lymphoma Summit. A virtual event seeking to educate, inform and challenge the thinking of patients with leukemia and lymphoma.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Image of woman with brown hair.
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Related Content
Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety: © stock.adobe.com.
April 28th 2025

Neoadjuvant Mitomycin C Shows Favorable Safety in Bladder Cancer

Jax DiEugenio
Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable safety.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
CHRISTIE GRIFFIN-JONES, MBA-HCM, B.S.N., RN, CPHQ, CRRN, and MIKELA PETTIGREW, B.S.N., RN, OCN
April 25th 2025

Commitment to Patients Is Driven by a Lasting Promise

Christie Griffin-Jones, MBA-HCM, B.S.N., RN, CPHQ, CRRN
Mikela Pettigrew, B.S.N., RN, OCN,, exemplifies extraordinary compassion and dedication. Every day, she fulfills a promise she made as a young caregiver.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Illustration of blood.
April 24th 2025

Dose-Limiting Toxicity Observation Phase Completed in CRS Trial for Lymphoma

Ryan Scott
In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation period was successfully completed.
MATTHEW MANGOLD, B.S.N., RN, and ERIN LONGSTRETH, M.S.N., RN, OCN, NEA-BC
April 22nd 2025

Advocacy and ‘Radiating Valor’ Have a Transformative Impact

Erin Longstreth, M.S.N., RN, OCN, NEA-BC